SG195110A1 - Pirfenidone and anti-fibrotic therapy in selected patients - Google Patents

Pirfenidone and anti-fibrotic therapy in selected patients

Info

Publication number
SG195110A1
SG195110A1 SG2013086541A SG2013086541A SG195110A1 SG 195110 A1 SG195110 A1 SG 195110A1 SG 2013086541 A SG2013086541 A SG 2013086541A SG 2013086541 A SG2013086541 A SG 2013086541A SG 195110 A1 SG195110 A1 SG 195110A1
Authority
SG
Singapore
Prior art keywords
pirfenidone
selected patients
fibrotic therapy
fibrotic
therapy
Prior art date
Application number
SG2013086541A
Other languages
English (en)
Inventor
Williamson Ziegler Bradford
Original Assignee
Intermune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intermune Inc filed Critical Intermune Inc
Publication of SG195110A1 publication Critical patent/SG195110A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG2013086541A 2011-05-25 2012-05-25 Pirfenidone and anti-fibrotic therapy in selected patients SG195110A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161489936P 2011-05-25 2011-05-25
US201161490057P 2011-05-26 2011-05-26
US201161523047P 2011-08-12 2011-08-12
US201161524961P 2011-08-18 2011-08-18
PCT/US2012/039538 WO2012162592A1 (en) 2011-05-25 2012-05-25 Pirfenidone and anti-fibrotic therapy in selected patients

Publications (1)

Publication Number Publication Date
SG195110A1 true SG195110A1 (en) 2013-12-30

Family

ID=47217770

Family Applications (1)

Application Number Title Priority Date Filing Date
SG2013086541A SG195110A1 (en) 2011-05-25 2012-05-25 Pirfenidone and anti-fibrotic therapy in selected patients

Country Status (11)

Country Link
US (1) US20150164874A1 (cg-RX-API-DMAC7.html)
EP (1) EP2713732A4 (cg-RX-API-DMAC7.html)
JP (1) JP6170040B2 (cg-RX-API-DMAC7.html)
KR (1) KR20140022048A (cg-RX-API-DMAC7.html)
AU (1) AU2012258575B2 (cg-RX-API-DMAC7.html)
CA (1) CA2835438A1 (cg-RX-API-DMAC7.html)
HK (1) HK1197159A1 (cg-RX-API-DMAC7.html)
IL (1) IL229226A0 (cg-RX-API-DMAC7.html)
MX (1) MX2013013752A (cg-RX-API-DMAC7.html)
SG (1) SG195110A1 (cg-RX-API-DMAC7.html)
WO (1) WO2012162592A1 (cg-RX-API-DMAC7.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008265595B2 (en) 2007-06-20 2014-12-04 PureTech LYT 100 Inc. Substituted N-Aryl pyridinones as fibrotic inhibitors
BR112013022766A2 (pt) * 2011-03-08 2016-12-06 Auspex Pharmaceuticals Inc método de administração de d-pirfenidona e kit
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
CA3280124A1 (en) 2013-07-31 2025-10-31 Avalyn Pharma Inc. Aerosol imatinib compounds and uses thereof
RU2692485C2 (ru) 2014-04-02 2019-06-25 Интермьюн, Инк. Противофиброзные пиридиноны
EP3194446B1 (en) * 2014-09-18 2022-10-26 Cedars-Sinai Medical Center Compositions and methods for treating fibrosis
DK3050574T3 (da) * 2015-01-28 2020-01-20 Univ Bordeaux Anvendelse af plerixafor til behandling og/eller forebyggelse af akutte forværringer af kronisk obstruktiv lungesygdom
US20180064662A1 (en) * 2015-03-05 2018-03-08 The General Hospital Corporation Novel compositions and uses of metformin agents
SG11201907673YA (en) * 2017-03-13 2019-09-27 Genfit Pharmaceutical compositions for combination therapy
US20210363259A1 (en) * 2017-08-22 2021-11-25 Biogen Ma Inc. Pharmaceutical compositions and dosage regimens containing anti-alpha(v)beta(6) antibodies
CA3140129A1 (en) * 2019-05-17 2020-11-26 The Regents Of The University Of California Mps modified peptides and use thereof
CN112239507A (zh) 2019-07-17 2021-01-19 鸿运华宁(杭州)生物医药有限公司 ETA抗体与TGF-β Trap的融合蛋白质,以及其药物组合物和应用
EP3821946A1 (en) * 2019-11-12 2021-05-19 Université de Strasbourg Anti-claudin-1 monoclonal antibodies for the prevention and treatment of fibrotic diseases
WO2021110805A1 (en) 2019-12-04 2021-06-10 Idorsia Pharmaceuticals Ltd Combination of an azetidine lpa1 receptor antagonist with pirfenidone and/or nintedanib for use in the treatment of fibrotic diseases
US20230129866A1 (en) * 2020-03-13 2023-04-27 Puretech Lyt 100, Inc. Methods of treating respiratory disease with deupirfenidone
CN114617890A (zh) * 2020-12-08 2022-06-14 四川夏派森医药科技有限公司 DH404在治疗SARS-CoV-2感染中的应用
CN112640887B (zh) * 2020-12-25 2022-05-13 武汉睿健医药科技有限公司 一种神经干细胞冻存液及其应用
WO2022266370A1 (en) * 2021-06-17 2022-12-22 Aria Pharmaceuticals, Inc. Sparsentan for treating idiopathic pulmonary fibrosis
CN114097807B (zh) * 2021-11-25 2023-05-05 兰州大学 巴多索隆类化合物在抗农业病原真菌中的用途
WO2023192646A1 (en) * 2022-03-31 2023-10-05 Puretech Lyt 100, Inc. Methods of treating fibrotic- and collagen-mediated diseases and disorders with deupirfenidone

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE420878T1 (de) * 2000-02-18 2009-01-15 Kyowa Hakko Kirin Co Ltd Isoxazol- und thiazolverbindungen und ihre verwendung als medikamente
CN1307997C (zh) * 2002-06-28 2007-04-04 图兰恩教育基金管理人 用于治疗肺纤维化的4-(4-甲基哌嗪-1-基甲基)-n-[4-甲基-3-(4-(吡啶-3-基)嘧啶-2-基氨基)苯基]-苯甲酰胺
WO2004103296A2 (en) * 2003-05-16 2004-12-02 Intermune, Inc. Methods of treating idiopathic pulmonary fibrosis
WO2005110478A2 (en) * 2004-04-13 2005-11-24 Intermune, Inc. Combination therapy for treating fibrotic disorders
WO2007119214A2 (en) * 2006-04-13 2007-10-25 Actelion Pharmaceuticals Ltd Endothelin receptor antagonists for early stage idiopathic pulmonary fibrosis
HUE052220T2 (hu) * 2006-09-08 2021-04-28 Abbvie Bahamas Ltd Interleukin-13 kötõfehérjék
AU2008265595B2 (en) * 2007-06-20 2014-12-04 PureTech LYT 100 Inc. Substituted N-Aryl pyridinones as fibrotic inhibitors
EP2389227A4 (en) * 2009-01-26 2012-08-08 Intermune Inc METHOD FOR THE TREATMENT OF ACUTE MYOCARDINE CARDS AND ASSOCIATED ILLNESSES THEREOF
GB2474748B (en) * 2009-10-01 2011-10-12 Amira Pharmaceuticals Inc Polycyclic compounds as lysophosphatidic acid receptor antagonists

Also Published As

Publication number Publication date
NZ617415A (en) 2017-07-28
US20150164874A1 (en) 2015-06-18
EP2713732A1 (en) 2014-04-09
JP6170040B2 (ja) 2017-07-26
WO2012162592A1 (en) 2012-11-29
JP2014518880A (ja) 2014-08-07
KR20140022048A (ko) 2014-02-21
HK1197159A1 (en) 2015-01-09
CA2835438A1 (en) 2012-11-29
EP2713732A4 (en) 2014-12-03
AU2012258575A1 (en) 2013-11-21
AU2012258575B2 (en) 2017-03-02
IL229226A0 (en) 2014-01-30
MX2013013752A (es) 2014-08-01

Similar Documents

Publication Publication Date Title
MX2013013752A (es) Pirfenidona y tratamiento anti-fibrotico en pacientes seleccionados.
ZA201409334B (en) N-substituted benzamides and their use in the treatment of pain
NZ707477A (en) Activin-actrii antagonists and uses for treating bone and other disorders
IL231536A (en) Indazole-3-carboxamides, pharmaceuticals containing them and their use in the treatment of diseases
MX356525B (es) Vectores de virus asociados con adeno (aav) para uso en terapia de genes de coroideremia.
SI2935303T1 (sl) 4'-fluoro-nukleozidi, 4'-fluoro-nukleotidi in njihovi analogi za zdravljenje HCV
NZ630805A (en) Pharmaceutical combinations comprising a thionucleotide analog
IL221874A (en) History of pyrimidine and their use in the treatment of respiratory diseases such as copd
MX2015006478A (es) Inhibidores de glutaminasa y metodos de empleo.
MX364220B (es) Metodos de tratamientos de fibrosis.
PH12015502302B1 (en) Treatment of allergic rhinitis using a combination of mometasone and olopatadine
ZA201402452B (en) Novel pyrimethanil formulations and uses thereof in the treatment of crops
MX2015013755A (es) Formulacion farmaceutica para uso en el tratamiento y/o prevencion de restenosis.
GB2515440B (en) Vesicular Formulations for use in the treatment of Rosacea
ZA201307058B (en) Use of polyaminoisoprenyl derrivatives in antobiotic or antisertic treatment
GB2510524A (en) Pulmonary hypertension
ZA201503266B (en) Pyidone derivatives and uses thereof in the treatment of tuberculosis
IL230751A0 (en) New peptides, preparations containing them and used in methods to treat metabolic, cardiac and immune diseases
MX362111B (es) Un metodo para mejorar la funcion hepatica.
MX351765B (es) Uso de sales de 3-carboxi-n-etil-n,n-dimetilpropan-1-aminio en el tratamiento de enfermedades cardiovasculares.
LT2699545T (lt) Nauji amino-pirolino dariniai ir jų naudojimas metabolinio sindromo prevencijai ir (arba) gydymui
EP2934699A4 (en) PLOD2 GENE STIMULATORS AND USE OF SAID STIMULATORS FOR TREATING SKIN
TN2013000404A1 (en) Use of 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium salts in the treatment of cardiovascular disease
TN2015000236A1 (en) Use of 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium or a pharmaceutically acceptable salt thereof in the treatment of atherosclerosis
UA70775U (ru) Способ лечения менингококцемии у детей